Abstracts tagged "dermatomyositis"

Abstract Number: 2673 • ACR Convergence 2025
Quantitative 18F-FDG PET/CT analysis reveals new patterns of muscle involvement and prognostic indicators in idiopathic inflammatory myopathies: beyond proximal muscle weakness
Fatma Basibuyuk¹, Melih Yigithan Bahadir², Gokce Kenar Artin², Amac Kiray², Recep Bekis² and İsmail Sari², ¹Dokuz Eylul University, Izmir, Turkey, ²Dokuz Eylül University, İzmir, Izmir, Turkey
Background/Purpose: To characterize muscle involvement in idiopathic inflammatory myopathies (IIMs) using detailed anatomical segmentation and volumetric 18F-FDG PET/CT analysis, and to evaluate the prognostic value…
Abstract Number: 2061 • ACR Convergence 2025
Tryptophan Metabolism Alteration Is Associated With Rapidly Progressive Interstitial Lung Disease Of Anti-MDA5+ Dermatomyositis
Hongjiang liu, Yixue Guo, Xinhua dai, beibei cui, bo chen, changpei li, shuyi liao, Junlong zhang and Qibing Xie, West China Hospital, Sichuan University, Chengdu, China (People's Republic)
Background/Purpose: Anti-melanoma differentiation-associated gene 5-positive dermatomyositis (MDA5+ DM) is an autoimmune condition associated with rapidly progressive interstitial lung disease (RP-ILD) and high mortality. Metabolic disturbances…
Abstract Number: 1212 • ACR Convergence 2025
Relapse in Idiopathic Inflammatory Myopathies: insights from extended MyoCite and Italian Consortia
Maria Rosa Pellico¹, Cristina Bochicchio², Claudia Iannone³, Lekshmi Minikumari Rahulan⁴, Marco Fornaro⁵, Ilaria Cavazzana⁶, Edoardo Conticini⁷, Masataka Kuwana⁸, Akira Yoshida⁹, Silvia Cavalli², Silvia Grazzini⁷, Alessia Gatti¹⁰, Giulio Lopinto¹¹, Paolo Semeraro¹², Thomas Patrick Sheeran¹³, Florenzo Iannone¹⁴, Vikas Agarwal¹⁵, Roberto Caporali¹⁶, Nicoletta Del pAPA¹ and Latika Gupta¹⁷, ¹ASST Pini-CTO, Clinical Rheumatology Unit, Milano, Italy, ²ASST Pini-CTO, Clinical Rheumatology Unit, Milan, Italy, ³University of Milan, Gaetano Pini CTO, Milano, Milan, Italy, ⁴Sanjay Gandhi Postgraduate Institute of Medical sciences Lucknow, Lucknow, Uttar Pradesh, India, ⁵Unit of Rheumatology, Department of Precision and Regenerative Medicine, Area Jonica (DiMePRe-J), University of Bari, Italy., Bari, Italy, ⁶Rheumatology and Clinical Immunology Unit, Clinical and Experimental Sciences Department, ERN ReCONNET, ASST Spedali Civili of Brescia and University of Brescia, Brescia, Italy, Brescia, Lombardia, Italy, ⁷Rheumatology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Italy, Siena, Italy, ⁸Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ⁹Department of Allergy and Rheumatology Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ¹⁰Rheumatology and Clinical Immunology Unit – ERN ReCONNET, ASST Spedali Civili and University of Brescia, Brescia, Lombardia, Italy, ¹¹Unit of Rheumatology, Department of Precision and Regenerative Medicine, Area Jonica (DiMePRe-J), University of Bari, Italy., Bari, ¹²Rheumatology and Clinical Immunology Unit, Clinical and Experimental Sciences Department, ERN ReCONNET, ASST Spedali Civili of Brescia and University of Brescia, Brescia, Italy, Brescia, Italy, ¹³Department of Rheumatology, The Royal Wolverhampton NHS Trust, Wolverhampton, UK; Rheumatology Department, Walsall Manor Hospital, Walsall, UK, Wolverhampton, United Kingdom, ¹⁴Rheumatology DiMePReJ, University of Bari, School of Medicine, Bari, Italy, Bari, Italy, ¹⁵Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, ¹⁶University of Milan and ASST Gaetano Pini-CTO, Milano, Italy, ¹⁷School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham; Royal Wolverhampton NHS Trust; Centre for Musculoskeletal Research, School of Biological Sciences, The University of Manchester, Manchester; Francis Crick Institute, London, Birmingham, UK, United Kingdom
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a group of rare and heterogeneous diseases. One of the greatest challenges in IIM management is defining and predicting…
Abstract Number: 0298 • ACR Convergence 2025
Inter-rater Reliability of Hand-Held Dynamometry in Patients with Idiopathic Inflammatory Myopathy
Niladri Bhowmick¹, Shashank Suresh², Didem Saygin³, Siamak Moghadam-Kia⁴, Dana Ascherman⁵, Chester V. Oddis⁵ and Rohit Aggarwal⁶, ¹University of Pittsburgh Medical Center, Pittsburgh, ²Atrium Health, Charlotte, NC, ³Rush University Medical Center, Chicago, IL, ⁴University of Pittsburgh Medical Center, Pittsburgh, PA, ⁵University of Pittsburgh, Pittsburgh, PA, ⁶University of Pittsburgh, Rheumatology and Clinical Immunology, Pittsburgh, United States of America, Pittsburgh, PA
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are characterized by symmetrical proximal muscle weakness. Accurate and reliable assessment of muscle strength is important for diagnosis, monitoring, and…
Abstract Number: 2672 • ACR Convergence 2025
Safety and efficacy of Upadacitinib in melanoma differentiation-associated gene 5-positive dermatomyositis with interstitial lung disease: a single-centre, retrospective, propensity score-matched cohort study
Can Xia¹, Wanlong Wu¹, Yan Ye¹, Jingjing Li², Runci Wang¹, Wenwen Xu³, Zhiwei Chen¹, Yakai Fu², Xia Lyu¹, Kaiwen Wang¹, Wei Fan¹, Jia Li¹, Xiaodong Wang², Shuang Ye⁴ and Qiong Fu⁵, ¹Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (People's Republic), ²Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, Shanghai, China (People's Republic), ³Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (People's Republic), ⁴Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China, Shanghai, Shanghai, China (People's Republic), ⁵Renji Hospital, Shanghai, Shanghai, China
Background/Purpose: Anti-melanoma differentiation-associated protein 5 (MDA5) antibody-positive dermatomyositis (MDA5+DM) is a distinct and severe subtype of dermatomyositis, frequently complicated by interstitial lung disease (ILD). Among…
Abstract Number: 2062 • ACR Convergence 2025
Immune Cell Signatures Associated with Disease Activity in Dermatomyositis Across Autoantibody Subtypes
Jeffrey Sagun¹, Melissa Leeolou¹, Nicholas Geraci², Andrew Bender³, Fatima Strand², David Fiorentino¹ and Kavita Sarin¹, ¹Department of Dermatology, Stanford University Medical Center, Stanford, CA, ²EMD Serono, Billerica, MA, ³AbbVie, Worcester, MA
Background/Purpose: Dermatomyositis (DM) is a heterogeneous multisystem autoimmune disease characterized by inflammation of the skin, muscle, and lung. Identifying the immune cells that drive disease…
Abstract Number: 1209 • ACR Convergence 2025
Beyond Muscle Strength: Functional Performance Measures Enhance Assessment of Disease Activity in Juvenile Dermatomyositis
Jia Shi¹, Alexander Carpenter², Christopher Wong², Qian Wang³, Christian Lood⁴ and Susan Shenoi⁵, ¹University of Washington, Seattle, WA, ²Division of Rheumatology, Seattle Children's Hospital and Research Center, Seattle, ³Peking Union Medical College Hospital, Beijing, Beijing, China (People's Republic), ⁴University of Washington, Division of Rheumatology, Seattle, ⁵Seattle Children's Hospital and Research Center, Mercer Island, WA
Background/Purpose: To evaluate the measurement properties of functional performance measures (FPMs)—broad jump (BJ) and 10-meter run (10MR)—for assessing muscle function and disease activity in children…
Abstract Number: 0297 • ACR Convergence 2025
Longitudinal Serum Proteomic Profiles – A Step Closer to Personalized Monitoring in Dermatomyositis
Natasha Le Blanc¹, Marie Hudson¹, Ana Cristina Gonzalez Sanchez², Lina Marcela Diaz Gallo² and Valerie Leclair³, ¹McGill University, Montréal, QC, Canada, ²Karolinska Institutet, Stockholm, Sweden, ³McGill University, Montréal, Canada
Background/Purpose: Dermatomyositis (DM) is a multisystemic immune mediated disease presenting with heterogeneous clinical features. Disease monitoring in DM relies in part on biomarkers of muscle…
Abstract Number: 2670 • ACR Convergence 2025
Real-World Experience of Anifrolumab in 24 Patients with Refractory Dermatomyositis: A Multicenter Retrospective Study.
Miriam Retuerto Guerrero¹, Clara Moriano², Ana Pareja-Martínez³, Natalia Molina-Esteban⁴, Jose Puig-Buendia⁵, Concepción Postigo-Llorente⁵, Ana Lopez-Ceron Cofiño⁶, Julia Martínez Barrio⁷, Paola Vidal-Montal⁸, Elena Sendagorta Cudos⁹, GUILLERMO GONZALEZ ARRIBAS¹⁰, Jaime Calvo¹¹, Juan Ramon De Dios¹², Juan María Blanco-Madrigal¹³, Paloma Vela Casasempere¹⁴, Javier Bachiller¹⁵, Concepción Fito-Manteca¹⁶, Carmen Ordas calvo¹⁷, Luisa Martos Cabrera¹⁸, Alejandro Sanchez Herrero¹⁹, Luis Ortega-Valin²⁰ and Elvira Diez Alvarez²¹, ¹Complejo Asistencial Universitario de León, Leon, Castilla y Leon, Spain, ²Hospital León, LEON, Castilla y Leon, Spain, ³Rheumatology. Hospital Universitario Infanta Leonor, Madrid, Madrid, Spain, ⁴Rheumatology. Hospital Universitario ¹² de octubre, Madrid, Madrid, Spain, ⁵Dermatology. Hospital universitario ¹² de octubre, Madrid, Madrid, Spain, ⁶Rheumatology. Complejo Asistencial Universitario de Soria, Soria, Castilla y Leon, Spain, ⁷Department of Rheumatology, Hospital Gregorio Marañón, Madrid, Spain, Madrid, Madrid, Spain, ⁸Rheumatology. Hospital Universitari de Bellvitge, Barcelona, Catalonia, Spain, ⁹Dermatology. Hospital universitario La Paz, Madrid, Madrid, Spain, ¹⁰Facultativo especialista, PALMA DE MALLORCA, Galicia, Spain, ¹¹Department of Rheumatology, Hospital Universitario Araba, School of Medicne, Universidad del País Vasco, BIOARABA Health Research Institute, Vitoria, Spain, Vitoria, Pais Vasco, Spain, ¹²Department of Rheumatology. Hospital Universitario Araba. Instituto de Investigación Sanitaria BIORABA., Vitoria, Pais Vasco, Spain, ¹³Rheumatology. Hospital Universitario Araba., Vitoria, Pais Vasco, Spain, ¹⁴Hospital General Universitario Alicante, Alicante, Comunidad Valenciana, Spain, ¹⁵Hospital Ramon y Cajal, Madrid, Madrid, Spain, ¹⁶Rheumatology. Hospital Universitario de Navarra., Pamplona, Navarra, Spain, ¹⁷Rheumatology. Hospital Universitario de Cabueñes., Gijon, Asturias, Spain, ¹⁸Dermatology. Hospital Universitario de La Princesa, Madrid, Madrid, Spain, ¹⁹Dermatology. Complejo Asistencial Universitario de Leon, Leon, Castilla y Leon, Spain, ²⁰Pharmacy. Complejo Asistencial Universitario de Leon, Leon, Castilla y Leon, Spain, ²¹Rheumatology. Complejo Asistencial Universitario de Leon, Leon, Castilla y Leon, Spain
Background/Purpose: Dermatomyositis (DM) is a systemic autoimmune disease marked by muscle weakness and characteristic cutaneous manifestations. Dysregulation of the Type I interferon (IFN-I) pathway plays…
Abstract Number: 2055 • ACR Convergence 2025
Construct Validity of Total Improvement Score (TIS) as an Endpoint for Clinically Meaningful Improvement in Multiple Patient-Centered Outcome Measures in Dermatomyositis
Anjana Chandrasekhara Pillai¹, Shiri Keret², Siamak Moghadam-Kia³, Chester V. Oddis⁴ and Rohit Aggarwal⁵, ¹PPCP, Pittsburgh, PA, ²Bnai Zion Medical Center, Atlit, Israel, ³University of Pittsburgh Medical Center, Pittsburgh, PA, ⁴University of Pittsburgh, Pittsburgh, PA, ⁵University of Pittsburgh, Rheumatology and Clinical Immunology, Pittsburgh, United States of America, Pittsburgh, PA
Background/Purpose: Total Improvement Score (TIS), as defined by the ACR/EULAR myositis response criteria, is increasingly employed as a primary endpoint in clinical trials for dermatomyositis…
Abstract Number: 1208 • ACR Convergence 2025
Neutrophil Activation in Juvenile Dermatomyositis: Associations with Muscle Function and Disease Progression
Jia Shi¹, Yang Wu², Aviya Levy³, Ting Wang⁴, Abhinav Janappareddi⁵, Payton Hermanson¹, Jorge A. Gonzalez-Chapa⁵, Qian Wang⁶, Susan Shenoi⁷ and Christian Lood⁵, ¹University of Washington, Seattle, WA, ²¹. Chinese Academy of Medical Sciences & Peking Union Medical College; ². Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Beijing, China; ³. University of Washington, Division of Rheumatology, Seattle, WA, USA, Beijing, China (People's Republic), ³Rady Children's Hospital, San Diego, CA, ⁴Division of Rheumatology, Seattle Children's Hospital and Research Center, Seattle, ⁵University of Washington, Division of Rheumatology, Seattle, ⁶Peking Union Medical College Hospital, Beijing, Beijing, China (People's Republic), ⁷Seattle Children's Hospital and Research Center, Mercer Island, WA
Background/Purpose: Juvenile dermatomyositis (JDM) is an inflammatory vasculopathy characterized by muscle weakness and systemic inflammation. This study aimed to investigate the clinical utility of neutrophil…
Abstract Number: 0290 • ACR Convergence 2025
Comparison of Organ Damage and Survival in Anti-synthetase Syndrome and Other Idiopathic Inflammatory Myopathies: An Analysis of Patients from Turkey
Ezgi Sahin¹, Omer Uludag², yasemin yalcinkaya³, Bahar Artim Esen⁴, Ahmet Gul³ and Murat Inanc³, ¹Istanbul University Istanbul Faculty of Medicine, Istanbul, Turkey, ²Istanbul University, Istanbul Faculty of Medicine, Division of Rheumatology, Istanbul, Turkey, ³Istanbul University, Istanbul Faculty of Medicine, Division of Rheumatology, Istanbul, Istanbul, Turkey, ⁴Istanbul University, Istanbul, Istanbul, Turkey
Background/Purpose: Idiopathic inflammatory myopathies (IIMs) are rare autoimmune diseases characterized by muscle weakness, often involving other organs such as the skin, lungs, and heart. Defined…
Abstract Number: 2669 • ACR Convergence 2025
RESET-Myositis: Clinical Trial Evaluating Rese-cel (Resecabtagene Autoleucel), A Fully Human, Autologous 4-1BB CD19-CAR T Cell Therapy in Idiopathic Inflammatory Myopathies
Erin Wilfong¹, Tahseen Mozaffar², Elie Naddaf³, Nizar Chahin⁴, Huifang Lu⁵, Iazsmin Bauer Ventura⁶, Courtney Little⁷, Carl diCasoli⁷, Claire Miller⁸, Jenell Volkov⁷, Daniel Nunez⁷, Thomas Furmanak⁷, Jason Stadanlick⁷, Larissa Ishikawa⁷, Zachary Vorndran⁷, Alexandra Ellis⁷, Jazmean Williams⁷, Steve Flanagan⁷, Quynh Lam⁸, Fatemeh Hadi-Nezhad⁸, Raj Tummala⁸, Samik Basu⁷ and David Chang⁹, ¹Vanderbilt University Medical Center, Nashville, TN, USA, Nashville, TN, ²University of California, irvine, Orange, CA, ³Mayo Clinic, Rochester, MN, ⁴Oregon Health & Science University, Portland, ⁵UT MD Anderson Cancer Center, Houston, TX, ⁶University of Chicago, Chicago, IL, ⁷Cabaletta Bio, Philadelphia, PA, ⁸Cabaletta Bio, Philadelphia, ⁹Cabaletta Bio, Bryn Mawr, PA
Background/Purpose: The goals of treatment for idiopathic inflammatory myopathy (IIM) are to eliminate or reduce inflammation, restore muscle performance, reduce morbidity, and improve a patient’s…
Abstract Number: 2053 • ACR Convergence 2025
A Prospective Study Unveils Damage Accrual and Myositis Specific Antibodies as Key Risk Factors for Mortality in Myositis
Agustin Hernández-López¹, Nancy R Mejía Domínguez², Yatzil Reyna Juárez³, María José Ostos Prado⁴, Beatriz Alcalá Carmona⁵, Jennifer Tiaré Balderas Miranda⁶, Carlos A. Núñez-Álvarez⁵, Marta E. Baños-Laredo⁷, Diana Gómez-Martín⁸ and Jiram Torres-Ruiz⁹, ¹Instituo Nacional de Ciencias Médicas y Nutricion Salvador Zubirán, Morelia, Michoacan de Ocampo, Mexico, ²Universidad Nacional Autónoma de México, Mexico City, Distrito Federal, Mexico, ³Instituto Politècnico Nacional, Tultitlán de Mariano Escobedo, Mexico State, Mexico, ⁴Instituto Nacional De Ciencias Médicas Y Nutrición Salvador Zubirán, Mexico City, Distrito Federal, Mexico, ⁵INCMNSZ, Cdmx, Distrito Federal, Mexico, ⁶Universidad Nacional Autónoma de México, Coyoacán, Federal District, Mexico, ⁷INCMNSZ, Cdmx, Mexico, ⁸INCMNSZ, Mexico city, Federal District, Mexico, ⁹INCMNSZ, Ciudad de México, Mexico
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a group of autoimmune diseases characterized by muscular inflammation that can affect any organ or system. Reported mortality rates…
Abstract Number: 1207 • ACR Convergence 2025
Cutaneous and Muscular Disease Trajectories in Adult Patients with Dermatomyositis
Jesus Valencia¹, Will Kelly¹, Sean Tackett², Amanda Finney¹, Jemima Albayda¹, Julie Paik³, Lisa Christopher-Stine¹ and Chris Mecoli⁴, ¹Johns Hopkins University, Baltimore, MD, ²Johns Hopkins University, Baltimore, ³Johns Hopkins Rheumatology, Baltimore, MD, ⁴Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Dermatomyositis (DM) is a rare autoimmune disease characterized by cutaneous manifestations and proximal muscle inflammation.1,2 Notably, the clinical course of muscular and cutaneous disease…

1
2
3
…
28
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].